Zytiga

Type: Product
Name: Zytiga
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

FDA Grants Fast Track Designation for Custirsen for mCRPC

Adherence to established prostate cancer quality of care measures is frequently low, with considerable regional variation.Drug no better than placebo in preventing erectile dysfunction after radiotherapy for prostate cancerPhase 3 trial launched for Xofigo ... [Published Chemotherapy Advisor - Apr 23 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 2 reports

Why Johnson & Johnson Is Outperforming the Dow

After setting record highs in 2013, the Dow Jones Industrials (DJINDICES: ^DJIDrug sales power consensus-beating 1Q earningsJ&J last Tuesday posted first-quarter earnings per share of $1.54, which was $0.06 higher than the Wall Street consensus. Revenue ... [Published Motley Fool - Apr 22 2014]
First reported Apr 20 2014 - Updated Apr 20 2014 - 1 reports

Why Johnson & Johnson's Patent Expiration Profile Is Fantastic

SummaryVery few firms have a more attractive investment profile than Johnson & Johnson. Johnson & Johnson boasts a cash-flow-derived Valuentum Dividend Cushion score of 2.2, and we don’t see us removing it from the Dividend Growth portfolio anytime soon. ... [Published Seeking Alpha - Apr 20 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

How Big Is the Threat to This Johnson & Johnson Blockbuster?

Johnson & Johnson ( NYSE: JNJ     ) has been one of the most successful big drug companies over the past three years. Despite an industry-wide sales drag caused by patent expiration on top-selling drugs, Johnson has skirted the headwind thanks to a wave ... [Published Motley Fool Discussion Boards - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Pharma driving J&J sales

Johnson & Johnson’s sales rose 3.5% year-on-year in the first quarter of 2014 to $18.1 billion, with net earnings of $4.7 billion.While sales in the consumer segment fell 3.2% to $3.5 billion, pharma grew 10.8% to $7.5 between January and March, overtaking ... [Published Pharmafocus - Apr 17 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

J&J hits one-week high as Q1 earnings beat, 2014 forecast boosted

3:52 pm by The company credited strong sales of new drugs: prostate cancer pill Zytiga ($512 million), hepatitis C medicine Olysio ($354 million) and Xarelto for preventing strokes ($319 million). Each is on pace to become blockbusters exceeding $1 billion ... [Published Proactive Investors USA - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

New drugs are J&J's Q1 heroes, spurring pharma giant to hike 2014 forecast

Weak consumer sales and flat medical device and diagnostics sales didn't stop Johnson & Johnson from trouncing analyst estimates Monday-or from raising its guidance for the year. A lineup of hot new meds powered the drug giant's first-quarter performance, ... [Published FiercePharma - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

Janssen's prostate cancer drug Zytiga now available in Trinidad & Tobago

The Chemistry , Food & Drugs Division of the Trinidad and Tobago Ministry of Health has approved Janssen's first orally administered androgen synthesis inhibitor ( testosterone ) medication 'Abiraterone Acetate' in the country for treatment of patients ... [Published BioPortfolio - Apr 15 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

Prostate cancer breakthroughs offer new hope for men

Men have lower life expectancy than women. This discrepancy is especially pronounced for African American men who live 6 fewer years than women.  According to the CDC, life expectancy in the US is 76 years for men compared to 81 for women.Over the past ... [Published News-Medical.Net - Apr 08 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

5 Biotechs With Prostate Cancer Treatments Worth Watching

In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to recently ... [Published Motley Fool Discussion Boards - Apr 05 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 2 reports

BTG annual sales to be at top end of guidance

Specialist healthcare group BTG expects full-year sales to be at the top end of the guidance after a 'transformational year'.Revenues for the financial year to March 31st are expected to be at the upper end of the £275-285m guidance range, which the company ... [Published London South East - Apr 03 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of Prostate Cancer

Research and Markets (http://www.researchandmarkets.com/research/rgdwwd/therapeutic_class) has announced the addition of the "" report to their offering. In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide, ... [Published Individual.com - Mar 27 2014]

Quotes

There it was in the words of Dominic Caruso, J&J's chief financial officer: "Despite the severe weather conditions, this was actually a very weak cold and flu season."
...is that the market believes that cabozantinib will have trouble competing against more established prostate cancer drugs like Johnson & Johnson "s Zytiga without strong evidence that the drug has a stellar efficacy profile. Indeed, the prostate cancercancer drug market has seen a number of newcomers of late, some of whom have struggled in this crowded space. That said, I believe Exelixis is now a bargain following this dramatic sell-off and is set to rebound. My thinking is simple: Some of the worst-selling prostate cancer drugs still see sales in the hundreds of millions and Exelixis" market cap has fallen to a mere $600 million...
"Given the company's strong financial position as demonstrated by its AAA debt rating, its strong cash flow generation and track record of consistently raising the dividend, we expect Johnson & Johnson to continue to grow the dividend in line with earnings, at a rate of 7 per cent per year, on average" Edward Jones analyst Judson Clark said in a note
...by successful new product launches and the continued growth of key products," said Alex Gorsky ( pictured ), chairman and chief executive, adding: "Our talented colleagues around the world continue to bring meaningful innovations to patients and customers, addressing significant unmet needs. We also advanced our near-term priorities and long-term growth drivers, positioning us well to deliver sustainable results."

More Content

All (128) | News (121) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
FDA Grants Fast Track Designation for Custirsen... [Published Chemotherapy Advisor - Apr 23 2014]
Why Johnson & Johnson Is Outperforming the Dow [Published Motley Fool - Apr 22 2014]
Why Johnson & Johnson Is Outperforming the Dow [Published Motley Fool Discussion Boards - Apr 22 2014]
Drug sales bolster J&J's bottom line [The Phila... [Published BusinessWeek - Apr 20 2014]
Why Johnson & Johnson's Patent Expiration Profi... [Published Seeking Alpha - Apr 20 2014]
Motley Fool: April 19, 2014 [Published St Augustine Herald - Apr 19 2014]
1 of These 3 Cratering Biotechs is a Buy [Published Motley Fool Discussion Boards - Apr 18 2014]
How Big Is the Threat to This Johnson & Johnson... [Published Motley Fool Discussion Boards - Apr 18 2014]
Earnings Roundup: Johnson & Johnson Results Are... [Published Motley Fool - Apr 17 2014]
Pharma driving J&J sales [Published Pharmafocus - Apr 17 2014]
JNJ Beats Estimates, Device Sales Flat [Published QMED - Apr 16 2014]
Johnson and Johnson Earnings Surprises With Blo... [Published Motley Fool - Apr 16 2014]
4 keeper stocks to save your sanity [Published MSN Money - Apr 16 2014]
A prescription for a healthy dividend [Published GlobeAdvisor - Apr 16 2014]
Johnson & Johnson 1st-qtr 2014 results beat exp... [Published Pharma Letter - Apr 16 2014]
J&J 1Q net up 8 percent on sales jump [Published Northwest Herald - Apr 15 2014]
Johnson & Johnson's Earnings Report Impresses [Published Motley Fool Discussion Boards - Apr 15 2014]
J&J hits one-week high as Q1 earnings beat, 201... [Published Proactive Investors USA - Apr 15 2014]
Johnson & Johnson's Management Discusses Q1 201... [Published Seeking Alpha - Apr 15 2014]
Johnson and Johnson Beats Earnings And Revenues... [Published Bidness Etc - Apr 15 2014]
J&J’s Pharmaceutical Success Drives Increase in... [Published Washington Post - Apr 15 2014]
Here’s Why Johnson & Johnson Had a Crazy Good F... [Published Wall St. Cheat Sheet - Apr 15 2014]
J&J Q1 net up 8 percent on sales jump, lower costs [Published Investor's Business Daily - Apr 15 2014]
J&J Earnings Beat Estimates As Pharma Sales Shine [Published Investor's Business Daily - Apr 15 2014]
J&J beats forecasts as strong sales of new drug... [Published Sharenet - Apr 15 2014]
New drugs are J&J's Q1 heroes, spurring pharma ... [Published FiercePharma - Apr 15 2014]
3 Health Care Stocks Bucking the S&P Downtrend [Published Motley Fool Discussion Boards - Apr 15 2014]
Johnson & Johnson Tops Street Views Amid Strong... [Published FOXBusiness.com - Apr 15 2014]
Tuesday’s Top Health Care Stories: Johnson & Jo... [Published Motley Fool - Apr 15 2014]
Johnson & Johnson Lifts FY14 Earnings Forecast ... [Published RTTNews.com - Apr 15 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Here’s Why Johnson & Johnson Had a Crazy Good F... [Published Wall St. Cheat Sheet - Apr 15 2014]
Source: http://www.flickr.com/photos/59937401@N07/ Shares of  Johnson & Johnson  ( NYSE:JNJ ) jumped as much as 1.6 percent in early trading on Tuesday after the healthcare and pharmaceutical company reported strong first-quarter results . Sales ...
Trinidad & Tobago Ministry of Health approves J... [Published PBR - News - Apr 14 2014]
The Chemistry, Food & Drugs Division of the Trinidad & Tobago Ministry of Health has approved the introduction of Janssen's Abiraterone Acetate in the country for the treatment of patients with metastatic castration-resistant prostate cancer. ...
Discount Packages on Global Trends and Developm... [Published PR.com Press Releases - Apr 04 2014]
New York, NY, April 04, 2014 --( PR.com )-- The global biotechnology and pharmaceutical market have seen significant positive sentiments in the recent years, especially with innovation contributing to the availability of a range of new treatments for ...
Research and Markets: Therapeutic Class Overvie... [Published Business Wire Health News - Mar 27 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x36zgs/therapeutic_class) has announced the addition of the "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of ...
Research and Markets: Global Prostate Cancer Th... [Published Business Wire Health News - Feb 14 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vhvpd8/prostate_cancer) has announced the addition of the "Global Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.